Skip to content
Adam Torkildson – Lifestyle
Author:
Tectonic Therapeutic
Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights
November 5, 2026
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
September 29, 2026
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
September 3, 2026
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
August 6, 2026
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
June 10, 2026